Furthermore, exploring mechanisms underlying gastric cancer patients with low CLDN18.2 expression is essential for devising targeted therapies and combined treatment strategies involving conventional radiotherapy, chemotherapy, and others. Here, CLDN18 is linked to gastric cancer.